Fentanyl - Generic Drug Details

What are the generic drug sources for fentanyl and what is the scope of patent protection?

Fentanyl is the generic ingredient in twenty-five branded drugs marketed by Janssen Pharms, Actavis Labs Ut Inc, Difgen Pharms, Kindeva, Lavipharm Labs, Mayne Pharma, Mylan Technologies, Noven, Specgx Llc, Zydus Pharms, Btcp Pharma, Adalvo, Abbott, Fresenius Kabi Usa, Hikma, Hospira, Watson Labs, Dr Reddys, Rising, Exela Pharma, Dr Reddys Labs Sa, Cephalon, Sentynl Theraps Inc, Actavis Labs Fl Inc, Par Pharm, and The Medicines Co, and is included in thirty-four NDAs. There are twenty-one patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Fentanyl has thirty-three patent family members in seventeen countries.

There are thirty-one drug master file entries for fentanyl. Five suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for fentanyl

International Patents:	33
US Patents:	21
Tradenames:	25
Applicants:	26
NDAs:	34
Drug Master File Entries:	31
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	22
Clinical Trials:	1,913
Patent Applications:	7,442
Drug Prices:	Drug price trends for fentanyl
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for fentanyl
What excipients (inactive ingredients) are in fentanyl?	fentanyl excipients list
DailyMed Link:	fentanyl at DailyMed

See drug prices for fentanyl

See drug sales revenues for fentanyl

Recent Clinical Trials for fentanyl

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Christopher D. Verrico	PHASE1
Baylor College of Medicine	PHASE1
Istanbul University - Cerrahpasa	NA

See all fentanyl clinical trials

Generic filers with tentative approvals for FENTANYL

Applicant	Application No.	Strength	Dosage Form
		EQ 0.05MG BASE/ML	INJECTABLE;INJECTION
		800MCG	TABLET;BUCCAL
		600MCG	TABLET;BUCCAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for fentanyl

Drug Class	Opioid Agonist
Mechanism of Action	Full Opioid Agonists

Medical Subject Heading (MeSH) Categories for fentanyl

Adjuvants, Anesthesia

Analgesics, Opioid

Anesthetics, Intravenous

Narcotics

Anatomical Therapeutic Chemical (ATC) Classes for fentanyl

N01AH	Opioid anesthetics
N01A	ANESTHETICS, GENERAL
N01	ANESTHETICS
N	Nervous system

N02AB	Phenylpiperidine derivatives
N02A	OPIOIDS
N02	ANALGESICS
N	Nervous system

Paragraph IV (Patent) Challenges for FENTANYL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SUBSYS	Sublingual Spray	fentanyl	0.1 mg/spray, 0.2 mg/spray, 0.6 mg/spray, 0.8 mg/spray, 1.2 mg/spray, 1.6 mg/spray	202788	1	2017-12-07
SUBSYS	Sublingual Spray	fentanyl	0.4 mg/spray	202788	1	2017-05-22

US Patents and Regulatory Information for fentanyl

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Specgx Llc	FENTANYL-62	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	077154-007	Jan 14, 2020	AB	RX	No	No
Dr Reddys Labs Sa	FENTANYL CITRATE	fentanyl citrate	TABLET;BUCCAL, SUBLINGUAL	206329-003	Aug 22, 2022		DISCN	No	No
Actavis Labs Ut Inc	FENTANYL-25	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	076709-001	Aug 20, 2007		DISCN	No	No
Btcp Pharma	SUBSYS	fentanyl	SPRAY;SUBLINGUAL	202788-005	Jan 4, 2012		DISCN	Yes	No	9,642,797		Y
Zydus Pharms	FENTANYL-87	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	209655-007	Jan 24, 2023		DISCN	No	No

Expired US Patents for fentanyl

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	DURAGESIC-75	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	019813-002	Aug 7, 1990	4,588,580*PED
Janssen Pharms	DURAGESIC-100	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	019813-001	Aug 7, 1990	4,060,084
Janssen Pharms	DURAGESIC-75	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	019813-002	Aug 7, 1990	4,060,084
Janssen Pharms	DURAGESIC-25	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	019813-004	Aug 7, 1990	4,588,580*PED
Janssen Pharms	DURAGESIC-50	fentanyl	FILM, EXTENDED RELEASE;TRANSDERMAL	019813-003	Aug 7, 1990	4,588,580*PED

EU/EMA Drug Approvals for fentanyl

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Kyowa Kirin Holdings B.V.	PecFent	fentanyl	EMEA/H/C/001164PecFent is indicated for the management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equi-analgesic dose of another opioid for a week or longer.	Authorised	no	no	no	2010-08-31
Takeda Pharma A/S	Instanyl	fentanyl	EMEA/H/C/000959Instanyl is indicated for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.	Authorised	no	no	no	2009-07-20
Teva B.V.	Effentora	fentanyl	EMEA/H/C/000833Effentora is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain., , BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain., , Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. ,	Authorised	no	no	no	2008-04-04
Incline Therapeutics Europe Ltd	Ionsys	fentanyl	EMEA/H/C/002715Ionsys is indicated for the management of acute moderate to severe post-operative pain in adult patients.	Withdrawn	no	no	no	2015-11-18
Eli Lilly and Company Limited	Recuvyra	fentanyl	EMEA/V/C/002239For the control of pain associated with orthopaedic and soft tissue surgery in dogs.	Withdrawn	no	no	no	2011-10-06

International Patents for fentanyl

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2009017837
Japan	5630877
Australia	2007208229
Japan	2009528272
Australia	2008282743	Sublingual fentanyl spray

Supplementary Protection Certificates for fentanyl

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0975367	122011000009	Germany		PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
0836511	CA 2006 00019	Denmark		PRODUCT NAME: FENTANYL HYDROCHLORID
0836511	122006000022	Germany		PRODUCT NAME: TRANSDERMAL IONTOPHORETISCH VERABREICHTES FENTANYL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/05/326/001 20060126
1635783	300653	Netherlands		PRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906
1769785	C300522	Netherlands		PRODUCT NAME: FENTANYL EN DOSERINGSAPPLICATOR; REG. NO/DATE: EU/2/11/127/001 20111006

Fentanyl Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Market Overview and Financial Performance

The global fentanyl market is characterized by its dual nature, encompassing both life-saving medical applications and illicit, highly potent substances. In the legitimate pharmaceutical sector, fentanyl is a critical component in pain management, particularly for severe or chronic pain and in anesthesia. Its high potency and rapid onset of action make it an indispensable tool in certain clinical settings.

The market for approved fentanyl-based therapeutics is substantial, driven by an aging global population, increasing prevalence of chronic diseases, and advancements in pain management strategies. Market research reports project steady growth in the legitimate fentanyl market. For instance, one report estimated the global fentanyl market size to reach USD 12.1 billion by 2027, growing at a compound annual growth rate (CAGR) of 5.2% from 2020 [1]. Another analysis projected the opioid pain management drugs market, which includes fentanyl, to reach USD 32.3 billion by 2027 [2].

Key players in the pharmaceutical fentanyl market include established pharmaceutical companies that manufacture and distribute fentanyl in various forms, such as transdermal patches, injectables, and lozenges. These companies operate under stringent regulatory oversight from bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

The financial trajectory of legitimate fentanyl products is influenced by several factors:

• Patent Expirations and Generics: As patents for branded fentanyl formulations expire, generic versions enter the market, leading to price erosion and increased competition. This can impact the revenue streams of originator companies but also expand patient access and reduce healthcare costs. For example, the expiry of patents for key extended-release fentanyl formulations has historically led to significant generic penetration.
• Therapeutic Advancements: Development of new delivery systems (e.g., nasal sprays, buccal films) and formulations offering improved safety profiles or patient convenience can create new market segments and revenue opportunities.
• Regulatory Scrutiny and Pricing Pressures: Increased public and governmental scrutiny regarding opioid use and addiction has led to tighter prescribing guidelines and pricing negotiations, which can affect market volumes and profitability.
• Market Access and Reimbursement: Payer policies and reimbursement rates for fentanyl products significantly influence market adoption and financial performance.

Conversely, the illicit fentanyl market poses a significant public health crisis and operates entirely outside of legal and financial frameworks. The financial aspect of illicit fentanyl is dominated by illegal drug trafficking organizations, with profits derived from the clandestine production and distribution of the substance. The low cost of synthesis for fentanyl compared to other opioids, combined with its extreme potency, makes it highly profitable for illicit manufacturers and distributors. This market's financial impact is measured not in revenue generated by legitimate entities, but in the immense societal costs associated with addiction, healthcare, and law enforcement.

Regulatory Landscape and Supply Chain Controls

The regulatory landscape governing fentanyl is exceptionally stringent due to its high potential for abuse and diversion. In the United States, fentanyl is classified as a Schedule II controlled substance under the Controlled Substances Act [3]. This classification imposes strict controls on its manufacture, distribution, prescription, and dispensing.

Key regulatory measures include:

• Manufacturing Quotas: The Drug Enforcement Administration (DEA) sets annual aggregate production quotas for fentanyl to ensure sufficient supply for legitimate medical and scientific needs while preventing diversion [4]. These quotas directly impact the production volumes for pharmaceutical manufacturers.
• Prescription Drug Monitoring Programs (PDMPs): States mandate the use of PDMPs, electronic databases that track controlled substance prescriptions. This helps identify potential over-prescribing and patient shopping for drugs.
• Dispensing Requirements: Pharmacists and healthcare providers must adhere to specific record-keeping and dispensing protocols for Schedule II substances. This often involves special prescription forms and verification processes.
• Import and Export Controls: Strict regulations govern the import and export of fentanyl and its precursors to prevent illicit trafficking.
• DEA Registration: All entities involved in the handling of fentanyl, from manufacturers to researchers, must be registered with the DEA and comply with its security and record-keeping requirements.

The supply chain for legitimate pharmaceutical fentanyl is highly controlled and monitored:

• Manufacturer Oversight: Pharmaceutical companies producing fentanyl are subject to rigorous inspection by regulatory bodies regarding Good Manufacturing Practices (GMPs).
• Wholesaler and Distributor Licensing: Only licensed and registered wholesalers and distributors can handle and transport controlled substances like fentanyl. These entities implement strict inventory controls and security measures.
• Pharmacy Security: Pharmacies are required to maintain secure storage for controlled substances and maintain accurate dispensing records.
• DEA Diversion Control Division: This division of the DEA is specifically tasked with preventing the diversion of controlled substances from legitimate channels into the illicit market. They conduct audits and investigations to ensure compliance.

The illicit fentanyl supply chain is characterized by its global nature and reliance on precursor chemicals, often sourced from countries like China and India, and then synthesized into fentanyl in clandestine laboratories, frequently located in Mexico, before being trafficked into markets such as the United States. This illegal network operates through various channels, including online marketplaces and street-level distribution, circumventing all legitimate regulatory controls.

Innovation and Research & Development

Research and development efforts in the legitimate fentanyl space are primarily focused on improving its therapeutic utility while mitigating associated risks. Innovation is driven by the need for more effective pain management solutions, particularly for populations with complex needs, and by the ongoing public health imperative to combat opioid addiction.

Areas of R&D include:

• Novel Delivery Systems: Development of advanced delivery mechanisms aims to provide more precise dosing, longer-lasting effects, or rapid relief with reduced abuse potential. Examples include:
  • Transdermal Patches: Next-generation patches with improved adhesion, consistent drug release, and potentially abuse-deterrent features.
  • Fast-Acting Oral Formulations: Sublingual tablets, buccal films, and nasal sprays that offer rapid onset of pain relief for breakthrough pain in cancer patients.
  • Implantable Devices: Long-acting implants for continuous pain management over extended periods.
• Abuse-Deterrent Formulations (ADFs): This is a significant area of research. ADFs are designed to make it more difficult for individuals to crush, dissolve, or otherwise extract the fentanyl for non-prescribed routes of administration (e.g., injection or snorting). While ADFs are not foolproof, they represent a substantial effort to reduce the abuse liability of opioid medications.
• Combination Therapies: Investigating the use of fentanyl in conjunction with other analgesics or non-opioid pain relief modalities to reduce the required fentanyl dose and minimize side effects.
• Antidotes and Addiction Treatment: Significant R&D is dedicated to developing and improving opioid overdose antidotes (e.g., naloxone) and medications for opioid use disorder (MOUD), such as buprenorphine and naltrexone. While not directly related to fentanyl therapeutics, this research is critical for mitigating the harms of opioid use.
• Understanding Mechanisms of Action: Continued research into the precise neurobiological mechanisms of fentanyl and other opioids can lead to the identification of novel therapeutic targets for pain management that do not rely on opioid receptor activation, thereby offering non-addictive alternatives.

The financial investment in R&D for legitimate fentanyl products is substantial, though it often competes for resources with other therapeutic areas. Pharmaceutical companies face high development costs, lengthy clinical trial phases, and the complex regulatory approval process. The potential for significant returns is tempered by the inherent risks associated with drug development and the evolving regulatory and societal landscape surrounding opioids.

For illicit fentanyl, R&D is not scientific innovation in the traditional sense. It involves clandestine chemists experimenting with synthesis routes and precursor chemicals to maximize potency and yield, and to evade detection. This "innovation" is driven by profit and driven by the desire to create more dangerous and addictive products.

Financial Performance Metrics and Market Drivers

Analyzing the financial performance of fentanyl products requires distinguishing between legitimate pharmaceutical entities and the illegal drug trade.

For Legitimate Pharmaceutical Companies:

Financial performance is assessed through standard metrics:

• Revenue: Sales figures for fentanyl-based products. This is influenced by prescription volumes, pricing, and market share. Companies often report revenue by therapeutic area or specific drug, and these figures are detailed in their quarterly and annual financial reports (e.g., 10-K filings with the SEC).
• Profit Margins: The profitability of fentanyl products, considering the cost of goods sold (COGS), research and development (R&D) expenses, marketing and sales costs, and regulatory compliance.
• Market Share: The percentage of the total market for specific fentanyl formulations or pain management drugs that a company holds.
• Return on Investment (ROI): The profitability of R&D investments in new fentanyl formulations or delivery systems.

Key market drivers for legitimate fentanyl products include:

• Prevalence of Pain: The number of individuals experiencing moderate to severe pain, particularly chronic pain conditions like cancer pain, neuropathic pain, and post-surgical pain.
• Aging Population: Older adults are more susceptible to chronic pain conditions, driving demand for effective analgesics.
• Oncology Market Growth: The increasing number of cancer diagnoses and the focus on palliative care and pain management in oncology create significant demand for potent analgesics like fentanyl.
• Surgical Procedures: Fentanyl is widely used in anesthesia and post-operative pain management. The volume of surgical procedures performed globally is a direct driver.
• Generic Competition: While it can lead to price erosion, the availability of generics expands patient access and can increase overall market volume.
• Regulatory Policies: Changes in prescribing guidelines, controlled substance scheduling, and pricing regulations can significantly impact sales volumes and profitability.

For the Illicit Fentanyl Market:

Financial performance is not tracked by standard business metrics. It is characterized by:

• High Profit Margins: Due to the low cost of synthesis and high potency, illicit fentanyl can generate extremely high profit margins for traffickers. A small amount of fentanyl can be diluted and sold, amplifying profits.
• Volume-Driven Revenue: The sheer volume of illicit drug sales contributes to substantial, albeit untaxed and unregulated, financial flows.
• Black Market Pricing: Prices fluctuate based on supply, demand, purity, and geographic location, often subject to enforcement actions and interdiction efforts.

Key drivers for the illicit fentanyl market are:

• Demand for Opioids: Driven by addiction, both from existing opioid users and new users seeking potent substances.
• Availability of Precursor Chemicals: Global supply chains for chemicals used in fentanyl synthesis are critical.
• Trafficking Networks: The efficiency and reach of international and domestic drug trafficking organizations.
• Low Production Cost: Compared to heroin or other natural opioids, fentanyl is chemically synthesized and can be produced relatively cheaply.
• Potency: Its extreme potency makes it attractive to users seeking a powerful high and allows traffickers to sell smaller quantities for higher profits.

The financial trajectory of the legitimate market is one of controlled growth and adaptation, while the illicit market represents a destructive force with immense financial implications driven by crime and addiction.

Competitive Landscape

The competitive landscape for fentanyl is bifurcated, reflecting its legitimate and illicit status.

Pharmaceutical Fentanyl Market:

This market is characterized by a mix of branded and generic manufacturers, with intense competition often driven by pricing, market access, and product differentiation through delivery systems.

• Branded Manufacturers: These companies focus on developing novel formulations, delivery systems, or ADFs. They often hold significant market share for their proprietary products. Examples of companies historically involved in fentanyl products include Janssen Pharmaceuticals (part of Johnson & Johnson) with Duragesic, Mylan (now Viatris) with its generic and branded offerings, and Insys Therapeutics (though now defunct due to legal issues) with its sublingual fentanyl spray.
• Generic Manufacturers: A substantial portion of the market is served by generic fentanyl products. Companies like Teva Pharmaceuticals, Hikma Pharmaceuticals, and numerous others compete on price and broad market availability. The presence of numerous generic competitors can lead to significant price competition, impacting profitability for all players.
• Specialty Pharma: Some smaller companies may focus on niche fentanyl products or specific delivery technologies.
• Contract Manufacturing Organizations (CMOs): CMOs play a role in manufacturing fentanyl APIs (Active Pharmaceutical Ingredients) and finished dosage forms for other pharmaceutical companies.

Competition in this sector is influenced by:

• Patent Protection: The duration and strength of patents on novel formulations and ADFs.
• Regulatory Approvals: The speed and success rate of obtaining FDA and other regulatory approvals for new products.
• Manufacturing Capabilities and Capacity: The ability to produce high-quality fentanyl products consistently and at scale, adhering to GMPs.
• Sales and Marketing Infrastructure: The reach and effectiveness of sales forces in engaging healthcare providers and securing market access.
• Pricing Strategies: Balancing competitive pricing with the need for profitability, especially in the face of reimbursement pressures.

Illicit Fentanyl Market:

The competitive landscape here is fragmented and extremely volatile, driven by criminal organizations.

• Drug Cartels and Transnational Criminal Organizations: These entities often control the large-scale production and trafficking of illicit fentanyl, managing complex supply chains from precursor sourcing to distribution.
• Independent Traffickers and Gangs: Smaller criminal groups and individual traffickers operate at local and regional levels, often sourcing their supply from larger organizations.
• Online Marketplaces: The dark web facilitates the clandestine sale and distribution of illicit drugs, creating a new competitive channel.

Competition in the illicit market is characterized by:

• Price Wars: Driven by oversupply or efforts to capture market share.
• Violence and Territory Control: Competition is often enforced through violence, with criminal groups vying for control over trafficking routes and distribution networks.
• Adaptability: The ability to evade law enforcement and adapt to changing precursor chemical availability or synthetic methods.
• Product Purity and Potency: Traffickers may compete on the strength of the product, which unfortunately correlates with increased overdose risk.

The stark contrast in competitive dynamics highlights the profound difference between a regulated industry focused on therapeutic benefit and an unregulated criminal enterprise driven by profit and disregard for human life.

Key Takeaways

• The global fentanyl market is bifurcated, with a legitimate pharmaceutical sector focused on pain management and anesthesia, and a dangerous illicit market fueling the opioid crisis.
• The legitimate fentanyl pharmaceutical market is projected for steady growth, driven by an aging population and chronic disease prevalence, with an estimated market size reaching over USD 12 billion by 2027.
• Stringent regulations, including DEA production quotas and PDMPs, govern the legitimate supply chain to prevent diversion.
• R&D in the legitimate sector focuses on advanced delivery systems, abuse-deterrent formulations, and combination therapies.
• Financial performance for pharmaceutical companies is measured by revenue, profit margins, and market share, driven by factors like patent expiry, generic competition, and pricing.
• The illicit fentanyl market operates with extremely high profit margins, driven by low production costs, high potency, and robust trafficking networks, posing a severe public health and societal cost.
• The competitive landscape for pharmaceutical fentanyl involves branded and generic manufacturers, while the illicit market is dominated by criminal organizations and is characterized by violence and volatility.

Frequently Asked Questions

1. What is the primary financial driver for legitimate fentanyl pharmaceutical sales? The primary financial driver is the demand for effective pain management in patients with severe or chronic pain, particularly those with cancer, and its use in anesthesia during surgical procedures.
2. How do patent expirations affect the financial trajectory of fentanyl products? Patent expirations lead to the introduction of generic versions, which typically results in price erosion and increased competition, impacting revenue for originator companies but expanding market access and affordability.
3. What specific regulatory measures are in place to control the legitimate fentanyl supply chain? Key measures include DEA manufacturing quotas, Prescription Drug Monitoring Programs (PDMPs), strict dispensing requirements for Schedule II substances, and import/export controls.
4. What are abuse-deterrent formulations (ADFs) in the context of fentanyl, and what is their financial impact? ADFs are designed to make it more difficult to misuse fentanyl by altering its physical or chemical properties. Their development represents significant R&D investment and can create new market opportunities for companies that successfully bring them to market.
5. How does the financial structure of the illicit fentanyl market differ from that of the legitimate pharmaceutical market? The illicit market generates revenue through illegal sales with no regulatory oversight or taxation, characterized by extremely high profit margins due to low production costs and high potency, whereas the legitimate market operates within a regulated framework with standard financial metrics like revenue and profit margins determined by sales and production costs.

---

Citations

[1] Grand View Research. (2021). Fentanyl Market Size, Share & Trends Analysis Report By Type (Injectable, Transdermal Patch, Others), By Application (Pain Management, Anesthesia, Others), By End-use (Hospitals, Clinics, Ambulatory Surgical Centers), By Region, And Segment Forecasts, 2020 - 2027. Retrieved from https://www.grandviewresearch.com/industry-analysis/fentanyl-market

[2] MarketsandMarkets. (2021). Opioid Pain Management Drugs Market - Global Forecast to 2027. Retrieved from https://www.marketsandmarkets.com/MarketReports/opioid-pain-management-drugs-market-173005276.html

[3] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act. Retrieved from https://www.dea.gov/node/18696

[4] U.S. Drug Enforcement Administration. (n.d.). Drug Scheduling. Retrieved from https://www.dea.gov/drug-scheduling